An update on gene therapy programs

Drug News and Perspectives

Volumn 22, Issue 7, 2009, Pages 435-440

  Romano, Gaetano ^a  

^a Temple University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AAV2 HRPE65V2; AD5F35LMPD1 2; ADENOVIRUS VECTOR; ANTINEOPLASTIC AGENT; AROMATIC LEVO AMINO ACID DECARBOXYLASE; BLOOD CLOTTING FACTOR 9; CARBOPLATIN; CELECOXIB; CHITOSAN DERIVATIVE; CHOLESTEROL DERIVATIVE; DOCETAXEL; EGEN 001; GENE THERAPY AGENT; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HYALURONIC ACID; IMMUNOMODULATING AGENT; INTEGRASE; INTERLEUKIN 12; MACROGOL DERIVATIVE; MELITTIN; MGN 1703; NANOCARRIER; NV 1020; OBP 301; ONCOVEX GM CSF; PLASMID DNA; POLYETHYLENEIMINE; RETROVIRUS VECTOR; SVV 001; TELOMELYSIN; UNCLASSIFIED DRUG; VIROTHERAPY AGENT;

ABDOMINAL PAIN; ADENO ASSOCIATED VIRUS; ADENOVIRUS; ADVANCED CANCER; BACTERIOPHAGE; CANCER GENE THERAPY; COLORECTAL CANCER; CONFERENCE PAPER; DISEASE SEVERITY; DRUG DOSE ESCALATION; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEVER; FLU LIKE SYNDROME; GENE; GENE DELIVERY SYSTEM; GENE THERAPY; HEMOPHILIA A; HEMOPHILIA B; HERPES SIMPLEX VIRUS 1; HUMAN; INJECTION SITE INDURATION; INJECTION SITE PAIN; LEBER CONGENITAL AMAUROSIS; LIVER METASTASIS; MELANOMA; MULTIPLE CYCLE TREATMENT; NASOPHARYNX CARCINOMA; NEUROENDOCRINE TUMOR; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; ONCOLYTIC VIROTHERAPY; OVARY CARCINOMA; PARKINSON DISEASE; PICORNAVIRUS; RETINA PIGMENT EPITHELIUM RPE 65 GENE; RNA INTERFERENCE; SENECA VALLEY VIRUS; SOLID TUMOR; STREPTOMYCES; TREATMENT RESPONSE;

ADENOVIRIDAE; ANIMALS; BLINDNESS; CLINICAL TRIALS AS TOPIC; GENE THERAPY; GENETIC VECTORS; HUMANS; NEOPLASMS; PARKINSON DISEASE;

EID: 72449164586     PISSN: 02140934     EISSN: None     Source Type: Journal    
DOI: 10.1358/dnp.2009.22.7.1410688     Document Type: Conference Paper

References (58)

1. Romano, G. Gene transfer in experimental medicine. Drug News Perspect 2003, 16(5): 267-276
2. Romano, G. Current development of lentiviral-mediated gene transfer. Drugs News Perspect 2005, 18(2): 128-134 (Pubitemid 40674902)
3. Romano, G. The controversial role of adenoviral-mediated gene transfer in gene therapy programs: where do we stand? Drugs News Perspect 2006, 19(2): 99-106.
4. Nandi, S. and Lesniak, M.S. Adenoviral virotherapy for malignant brain tumors. Expert Opin Biol Ther 2009, 9(6): 737-747
5. Cody, J.J. and Douglas, J.T. Armed replicating adenoviruses for cancer virotherapy. Cancer Gene Ther 2009, 16(6): 473-488
6. Todo, T. "Armed" oncolytic herpes simplex viruses for brain tumor therapy. Cell Adh Migr 2008, 2(3): 208-213
7. Ogawa, F., Takaoka, H., Iwai, S. et al. Combined oncolytic virotherapy with herpes simplex virus for oral squamous cell carcinoma. Anticancer Res 2008, 28(6A): 3637-3645
8. Hales, L.M., Knowles, N.J., Reddy, P.S. et al. Complete genome sequence analysis of Seneca Valley virus-001, a novel oncolytic Picornavirus. J Gen Virol 2008, 89(Pt. 5): 1265-1275
9. Venkataraman, S., Reddy, S.P., Loo, J. et al. Structure of Seneca Valley Virus-001: an oncolytic Picornavirus representing a new genus. Structure 2008, 16(10): 1555-1561
10. Russell, S.J., Peng, K.W. Measles virus for cancer therapy. Curr Top Microbiol Immunol 2009, 330: 213-241.
11. Yu, Y.A., Galanis, C., Woo, Y. et al. Regression of human pancreatic tumor xenografts in mice after a single systemic injection of recombinant vaccinia virus GLV-1h68. Mol Cancer Ther 2009, 8(1): 141-151
12. Prestwich, R.J., Errington, F., Ilett, E.J. et al. Tumor infection by oncolytic reovirus primes adaptive antitumor immunity. Clin Cancer Res 2008, 14(22): 7358-7366
13. Altomonte, J., Wu, L., Meseck, M. et al. Enhanced oncolytic potency of vesicular stomatitis virus through vector-mediated inhibition of NK and NKT cells. Cancer Gene Ther 2009, 16(3): 266-278
14. Nemunaitis, J., Tong, A., Nemumaitis, M. et al. Phase I study of introtumoral injection with telomerase specific replication competent oncolytic adenovirus, Telomelysin (OBP-301) in advanced cancer. 12th Annu Meet Am Soc Gene Ther (ASGT) (May 27-31, San Diego) 2009, Abst 742.
15. Senzer, N.N., Kaufman, H., Amatruda, T. et al. Updated results of a phase II clinical trial with a second generation, gene-modified, immune-enhanced, oncolytic herpes virus in unresectable metastatic melanoma. 12th Annu Meet Am Soc Gene Ther (ASGT) (May 27-31, San Diego) 2009, Abst 225.
16. Nemunaitis, J., Geevarghese, S.K., D. Geller, D.A. et al. Phase II efficacy results using an oncolytic herpes simplex virus (NV1020) in patients with colorectal cancer metastatic to liver (mCRC). 12th Annu Meet Am Soc Gene Ther (ASGT) (May 27-31, San Diego) 2009, Abst 792.
17. Senzer, N.N., Stephenson, J.J., Rudin, C.M. et al. Phase I study of Seneca Valley Virus (SVV-001), a replication competent oncolytic virus, in patients with neuroendocrine (NE) cancers. 12th Annu Meet Am Soc Gene Ther (ASGT) (May 27-31, San Diego) 2009, Abst 4.
18. Anwer, K., Barnes, M.N., Fewell, J.G. et al. Clinical development of a DNA-Based IL-12 therapeutic for the treatment of recurrent ovarian cancer. 12th Annu Meet Am Soc Gene Ther (ASGT) (May 27-31, San Diego) 2009, Abst 546.
19. Teo, M., Wang, P., Chia, J. et al. Phase II study of adenoviral vector (Ad3f35) transduced autologous dendritic cells in combination with celecoxib in patients with metastatic nasopharyngeal carcinoma. 12th Annu Meet Am Soc Gene Ther (ASGT) (May 27-31, San Diego) 2009, Abst 241.
20. Deyrup, A.T. Epstein-Barr virus-associated epithelial and mesenchymal neoplasms. Hum Pathol 2008, 39(4): 473-483
21. Weihrauch, M.R., Schmidt, M., Richly, H. et al. Phase I trial of MGN1703, a novel TLR9-agonist, in patients with metastatic malignancies. 12th Annu Meet Am Soc Gene Ther (ASGT) (May 27-31, San Diego) 2009, Abst 574.
22. Olanow, C.W., Stern. M.B. and Sethi, K. The scientific and clinical basis for the treatment of Parkinson disease (2009). Neurology 2009, 72(21 Suppl 4): S1-136.
23. Björklund, T. and Kirik, D. Scientific rationale for the development of gene therapy strategies for Parkinson's disease. Biochim Biophys Acta 2009, 1792(7): 703-713
24. Muramatsu, S., Fujimoto, K., Kato, S. et al. Aromatic L-amino acid decarboxylase gene therapy for Parkinson's disease: Results from an open-label, phase I trial. 12th Annu Meet Am Soc Gene Ther (ASGT) (May 27-31, San Diego) 2009, Abst 429.
25. Bankiewicz, K.S., Valtes, F., Starr, P.A. et al. Imaging of AAV2-hAADC delivery in a phase I study of AAV2-hAADC gene therapy for Parkinson's disease. 12th Annu Meet Am Soc Gene Ther (ASGT) (May 27-31, San Diego) 2009, Abst 505.
26. Cai, X., Conley, S.M., Naash, M.I. RPE65: role in the visual cycle, human retinal disease, and gene therapy. Ophthalmic Genet 2009, 30(2): 57-62.
27. Bennett, J., Maguire, A.M., Wright, J.F. et al. Gene therapy-mediated reversal of congenital blindness: Demonstration of efficacy in a phase 1 safety trial. 12th Annu Meet Am Soc Gene Ther (ASGT) (May 27-31, San Diego) 2009, Abst 426.
28. Jacobs, J.B., Dell'osso, L.F., Wang, Z.I. et al. Using the NAFX to measure the effectiveness over time of gene therapy in canine LCA. Invest Ophthalmol Vis Sci 2009, Advance publication.
29. Romano, G., Marino, I.R. Pentimalli, F. et al. Insertional mutagenesis and development of malignancies induced by integrating gene delivery systems: Implications for the design of safer gene-based interventions in patients. Drugs News & Perspect 2009, 22(4): 185-196
30. Giordano, A., Fucito, A., Romano, G. and Marino, I.R. Carcinogenesis and environment: The cancer stem cell hypothesis and implications for the development of novel therapeutics and diagnostics. Front Biosci 2007, 12: 3475-82.
31. Gan, D.D., Macatuso, M., Cinti, C. et al. How does a normal cell become a cancer cell? J Exp Clin Cancer Res 2003, 22(4): 509-516
32. Romano, G. The role of adult stem cells in carcinogenesis. Drug News Perspect 2005, 18(9): 555-559 (Pubitemid 43251106)
33. Cavazzana-Calvo, M., Hacein-Bey, S., De Saint Basile, G. et al. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 2000, 288(5466): 669-672 (Pubitemid 30241569)
34. Romano, G., Claudio, P.P., Tonini, T. and Giordano, A. Human immunodeficiency virus type 1 (HIV-1) derived vectors: safety considerations and controversy over therapeutic applications. Eur J Dermatol 2003, 13(5): 424-429 (Pubitemid 37305084)
35. Marshall, E. Gene therapy a suspect in leukemia-like disease. Science 2002, 298(5591): 34-35.
36. Buckley, R.H. Gene therapy for SCID - A com- plication after remarkable progress. Lancet 2002, 360(9341): 1185-1186
37. Check, E. Second cancer halts gene therapy clinical trials. Nature 2003, 421(6921): 305. (Pubitemid 36157908)
38. Hacein-Bey-Abina, S., Von Kalle, C., Schmidt, M. et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 2003, 302(5644): 415-419 (Pubitemid 37296260)
39. McCormack, M.P. and Rabbitts, T.H. Activation of the T-cell oncogene LMO2 after gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 2004, 350(9): 913-922 (Pubitemid 38252539)
40. Pike-Overzet, K., van der Burg, M., Wagemaker, G. et al. New insights and unresolved Issues regarding insertional mutagenesis in X-linked SCID gene therapy. Mol Ther 2007, 15(11): 1910-1916 (Pubitemid 350011729)
41. Baum, C. What are the consequences of the fourth case? Mol Ther 2007, 15(8): 1401-1402
42. Edelstein, M.L., Abedi, M.R. and Wixon, J. Gene therapy clinical trials worldwide to 2007 - An update. J Gene Med 2007, 9(10): 833-42.
43. Romano, G. Current development of nonviral-mediated gene transfer. Drug News Perspect 2007, 20(4): 227-231 (Pubitemid 47242191)
44. Romano, G. An overview on gene therapy programs. Drug News Perspect 2008, 21(6): 345-351
45. Philpott, N.J. and Thrasher, A.J. Use of nonintegrating lentivirol vectors for gene therapy. Hum Gene Ther 2997, 18(6): 483-489
46. Vargas, J., Gusella, G,L,, Najfeld, V. et al. Novel integrase-defective lentiviral episomal vectors for gene therapy. Hum Gene Ther 2004, 15(4): 361-372. (Pubitemid 38469778)
47. Tarskikh, A.V., Ershler, M.A., Drize, N.J. et al. Long-term persistence of a nonintegrated letnivirol vector in mouse hematopoietic stem cells. Exp Hematol 2005, 33(8): 873-882
48. Apolonia, L., Waddington, S.N., Fernandes, C. et al. Stable gene transfer to muscle using non-integrating lentiviral vectors. Mol Ther 2007, 15(11): 1947-1954 (Pubitemid 350011734)
49. Nightingale, S.J., Hollis, R.P., Pepper, K.A. et al. Transient gene expression by nonintegrating lentiviral vectors. Mol Ther 2006, 13(6): 1121-1132
50. Baiker, A., Maarcker, C., Piechaczek, C. et al. Mitotic stability of an episomal vector containing a human scaffold/matrix-attached region is provided by association with nuclear matrix. Nat Cell Biol 2000, 2(3): 182-184 (Pubitemid 30781135)
51. Lufino, M.M., Manservigi, R. and Wade-Martins, R. An S/MAR-based infectious episomal DNA expression vector provides long-term regulated functional complementation of LDLR deficiency. Nucleic Acids Res 2007, 35(15): e98.
52. Papapetrou, E.P., Ziros, P.G., Micheva, I.D. et al. Gene transfer into human hematopoietic progenitor cells with an episomal vector carrying an S/MAR element. Gene Ther 2006, 13(1): 40-51.
53. Duceppe, N., Sandras, M.G. and Tabrizian, M. Photo-inducible chitosan/hyaluronic acid DNA nanocarriers; in-vitro evaluation. 12th Annu Meet Am Soc Gene Ther (ASGT) (May 27-31, San Diego) 2009, Abst 492.
54. Kurosaki, T., Kitahara, T., To, H. Pulmonary gene delivery of hybrid vector, lipopolyplex containing N-lauroylsarcosine, via systemic route. 12th Annu Meet Am Soc Gene Ther (ASGT) (May 27-31, San Diego) 2009, Abst 158.
55. Baumhover, N.J., Anderson, K., Rice, K.G. Development of novel intercalating-fusogen bioconjugates as gene delivery agents. 12th Annu Meet Am Soc Gene Ther (ASGT) (May 27-31, San Diego) 2009, Abst 20.
56. Huang, X., Guo, H., Tammana, S. et al. Genome-wide analysis of Sleeping Beauty (SB), piggyBac and Tol2 transposon mediated integration in human primary T cells. 12th Annu Meet Am Soc Gene Ther (ASGT) (May 27-31, San Diego) 2009, Abst 863.
57. Chavez, C.L., Keravala, A., Woodard, L.E. and Calos, M.P. Longevity of phiC31 integrase expression in mouse liver. 12th Annu Meet Am Soc Gene Ther (ASGT) (May 27-31, San Diego) 2009, Abst 862.
58. Ward, N.J., Apolonia, L., Cochrane M. et al. Nonintegrating lentiviral vectors for treatment of haemophilia B. 12th Annu Meet Am Soc Gene Ther (ASGT) (May 27-31, San Diego) 2009, Abst 808.